S
KNTE

SignatureFD’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

SignatureFD’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-119
Closed -$726 – 3403
2022
Q4 		$726 Sell
119
-846
-88% -$6.89K ﹤0.01% 3039
2022
Q3 		$12K Buy
965
+157
+19% +$2.06K ﹤0.01% 2013
2022
Q2 		$10K Sell
808
-469
-37% -$4.37K ﹤0.01% 2136
2022
Q1 		$14K Buy
1,277
+1,074
+529% +$11.8K ﹤0.01% 2026
2021
Q4 		$4K Sell
203
-16
-7% -$337 ﹤0.01% 2529
2021
Q3 		$5K Buy
219
+160
+271% +$3.48K ﹤0.01% 2389
2021
Q2 		$1K Buy
+59
New +$1.5K ﹤0.01% 2883

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SignatureFD's KNTE Position: Q1 2023 in Review

SignatureFD sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q1 2023, closing a stake of 119 shares — an estimated $726 sold.

SignatureFD first reported a position in KNTE in Q2 2021 and held it in 7 quarters. The position peaked at $14K in Q1 2022. 71 funds tracked by Wall St. Rank hold KNTE as of Q1 2023.

  • SignatureFD reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • SignatureFD sold 119 Kinnate Biopharma Inc. Common Stock shares in Q1 2023, an estimated $726.
  • SignatureFD first reported a position in Kinnate Biopharma Inc. Common Stock in Q2 2021 and held it in 7 quarters.
  • SignatureFD's Kinnate Biopharma Inc. Common Stock position peaked at $14K in Q1 2022.
  • 71 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q1 2023.

Based on SignatureFD's 13F filing for Q1 2023, filed 28 Apr 2023.